Skip to main content

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Mild to Moderate Alzheimer’s Disease

Open
  • Protocol code: GV1001-AD-CL2-007
  • EudraCT code: 2021-004809-40
  • Research group: Neurovascular Diseases
  • Service: Neurology
  • Principal investigator:  Delgado Martínez, Maria Pilar
  • Pathology: Malalties del sistema nerviós
  • Phase: Fase II
  • Status: Recruiting volunteers